Ovid Therapeutics (NASDAQ:OVID) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 […]

Related Keywords

United States ,Jeremym Levin , ,Wealth Management ,Sg Americas Securities ,Ovid Therapeutics Inc ,Nasdaq ,Securities Exchange Commission ,Connor Clark Lunn Investment Management Ltd ,Ovid Therapeutics ,Free Report ,Get Free Report ,Exchange Commission ,Point Capital ,Lunn Investment Management ,Therapeutics Inc ,Ovid Therapeutics Daily ,Nasdaq Ovid ,Covid ,Medical ,Initiated Coverage ,Hc Wainwright ,